StockWatch: Novartis Loses More than Market Value After Phase III Failure
Phase 3negativepelacarsenrapcabtagene autoleucelNegative
AI Analysis
Summary
Novartis and Ionis Pharmaceuticals reported that pelacarsen failed its Phase III trial for cardiovascular risk reduction in Lp(a) disease. Additionally, Novartis paused eight trials for CAR-T therapy rap-cel after three patient deaths from hemophagocytic syndrome, representing multiple clinical setbacks for the company.
Clinical Trial Data
Outcome Details
pelacarsen failed Phase III Lp(a)HORIZON trial by missing primary endpoint of reducing cardiovascular events risk versus placebo
Importance:9/10
Sentiment:
-0.95
Phase 3 failurecardiovascularCAR-T safety concernsclinical setbackstock decline
Read the original article
Published by GEN - Genetic Engineering & Biotech News on September 13, 2026 8:19 PM